NASDAQ:IOVA

Iovance Biotherapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy IOVA

*Your capital is at risk

$3.79

-0.310 (-7.56%)

At Close: Jun 03, 2026

Iovance Biotherapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 87.64. In total, the insiders bought 3.13M and sold 282.82K IOVA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	87.64
● Buy	3.13M shares
● Sell	282.82K shares
74% Buy Activity Weak Negative Correlation
Buy Signal Medium Confidence Mar 09, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 87.64. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 11, 2026 Sell	Common Stock F-InKind	Kirby Daniel Gordon Chief Commercial Officer	Officer	2 435 Value: $9K
May 11, 2026 Buy	Common Stock M-Exempt	Kirby Daniel Gordon Chief Commercial Officer	Officer	10 000 Value: $37.0K
May 11, 2026 Buy	Restricted Stock Units M-Exempt	Kirby Daniel Gordon Chief Commercial Officer	Officer	10 000 Value: $37.0K
Mar 09, 2026 Buy	Restricted Stock Units A-Award	Bilinsky Igor Chief Operating Officer	C-Suite Officer	117 500 Value: $635.7K
Mar 09, 2026 Buy	Restricted Stock Units A-Award	Roche Corleen M. Chief Financial Officer	C-Suite Officer	132 200 Value: $715.2K
Mar 09, 2026 Buy	Restricted Stock Units A-Award	Vogt Frederick G Interim CEO & General Counsel	CEO / President	235 000 Value: $1.27M
Mar 09, 2026 Buy	Restricted Stock Units A-Award	Puri Raj K. Chief Regulatory Officer	Officer	117 500 Value: $635.7K
Mar 09, 2026 Buy	Restricted Stock Units A-Award	Graf Finckenstein Friedrich Chief Medical Officer	Officer	58 750 Value: $317.8K
Mar 09, 2026 Buy	Restricted Stock Units A-Award	Kirby Daniel Gordon Chief Commercial Officer	Officer	132 200 Value: $715.2K
Mar 05, 2026 Buy	Restricted Stock Units M-Exempt	Bilinsky Igor Chief Operating Officer	C-Suite Officer	31 246 Value: $143.1K
Mar 05, 2026 Sell	Common Stock F-InKind	Bilinsky Igor Chief Operating Officer	C-Suite Officer	16 628 Value: $76.2K
Mar 05, 2026 Buy	Common Stock M-Exempt	Bilinsky Igor Chief Operating Officer	C-Suite Officer	31 246 Value: $143.1K
Mar 05, 2026 Buy	Restricted Stock Units M-Exempt	Puri Raj K. Chief Regulatory Officer	Officer	39 059 Value: $178.9K
Mar 05, 2026 Sell	Common Stock F-InKind	Puri Raj K. Chief Regulatory Officer	Officer	18 360 Value: $84.1K
Mar 05, 2026 Buy	Restricted Stock Units M-Exempt	Graf Finckenstein Friedrich Chief Medical Officer	Officer	31 246 Value: $143.1K
Mar 05, 2026 Buy	Common Stock M-Exempt	Vogt Frederick G Interim CEO & General Counsel	CEO / President	62 493 Value: $286.2K
Mar 05, 2026 Sell	Common Stock F-InKind	Vogt Frederick G Interim CEO & General Counsel	CEO / President	26 755 Value: $122.5K
Mar 05, 2026 Buy	Restricted Stock Units M-Exempt	Vogt Frederick G Interim CEO & General Counsel	CEO / President	62 493 Value: $286.2K
Mar 05, 2026 Buy	Common Stock M-Exempt	Graf Finckenstein Friedrich Chief Medical Officer	Officer	31 246 Value: $143.1K
Mar 05, 2026 Sell	Common Stock F-InKind	Graf Finckenstein Friedrich Chief Medical Officer	Officer	16 520 Value: $75.7K
Mar 05, 2026 Buy	Common Stock M-Exempt	Puri Raj K. Chief Regulatory Officer	Officer	39 059 Value: $178.9K
Mar 02, 2026 Sell	Common Stock F-InKind	Puri Raj K. Chief Regulatory Officer	Officer	2 798 Value: $10.6K
Mar 02, 2026 Buy	Restricted Stock Units M-Exempt	Bilinsky Igor Chief Operating Officer	C-Suite Officer	3 517 Value: $13.3K
Mar 02, 2026 Sell	Common Stock F-InKind	Bilinsky Igor Chief Operating Officer	C-Suite Officer	6 903 Value: $26.2K
Mar 02, 2026 Buy	Restricted Stock Units M-Exempt	Vogt Frederick G Interim CEO & General Counsel	CEO / President	10 418 Value: $39.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IOVANCE BIOTHERAPEUTICS, INC.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or pers...

Read Full Profile Here